Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
November 30, 2023 09:45 ET
|
Biostax Corp
Orlando, FL, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biostax Corp., (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, proudly announces its participation in the upcoming U.S....
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
November 15, 2023 09:30 ET
|
Biostax Corp
Orlando, FL, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Influential Business Leader Roger...
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
November 02, 2023 10:10 ET
|
Biostax Corp
Orlando, FL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of...
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
October 24, 2023 09:15 ET
|
Biostax Corp
ORLANDO, Fla., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX), a leading public company specializing in healthcare solutions, today announced a milestone in its transformative...
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
September 14, 2023 09:15 ET
|
Immune Therapeutics, Inc.
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of...
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
August 29, 2023 09:05 ET
|
Immune Therapeutics, Inc.
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a...
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
August 15, 2023 09:05 ET
|
Immune Therapeutics, Inc.
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have...
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
April 20, 2023 09:05 ET
|
Immune Therapeutics, Inc.
Orlando, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine and Statera Biopharma...
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
March 01, 2023 09:34 ET
|
Immune Therapeutics, Inc.
ORLANDO, March 01, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development and...
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
November 09, 2022 17:00 ET
|
Immune Therapeutics, Inc.
Orlando, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that its Chief Executive Officer, President, and Director, Stephen...